Formulation Strategies to Overcome Amphotericin B Induced Toxicity
Molecular Pharmaceutics · 04.11.2024 · 21 (11) · 5392-5412
DOI: 10.1021/acs.molpharmaceut.4c00485 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, online erschienen am 07.10.2024. Verfasst von Sanat Kumar Dash und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Birla Institute of Technology and Science Pilani (BITS Pilani), Pilani Campus, Pilani, Rajasthan 333031, India. Hauptthemen laut MEDLINE: Amphotericin B, Antifungal Agents. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 157 Literaturangaben.
Abstract (Originalsprache)
Fungal infection poses a major global threat to public health because of its wide prevalence, severe mortality rate, challenges involved in diagnosis and treatment, and the emergence of drug-resistant fungal strains. Millions of people are getting affected by fungal infection, and around 3.8 million people face death per year due to fungal infection, as per the latest report. The polyene antibiotic AmB has an extensive record of use as a therapeutic moiety against systemic fungal infection and leishmaniasis since 1960. AmB has broad-spectrum fungistatic and fungicidal activity. AmB exerts its therapeutic activity at the cellular level by binding to fungal sterol and forming hydrophilic pores, releasing essential cellular components and ions into the extracellular fluid, leading to cell death. Despite using AmB as an antifungal and antileishmanial at a broad scale, its clinical use is limited due to drug-induced nephrotoxicity resulting from binding the aggregated form of the drug to mammalian sterol. To mitigate AmB-induced toxicity and to get better anti-fungal therapeutic outcomes, researchers have developed nanoformulations, self-assembled formulations, prodrugs, cholesterol- and albumin-based AmB formulations, AmB-mAb combination therapy, and AmB cochleates. These formulations have helped to reduce toxicity to a certain extent by controlling the aggregation state of AmB, providing sustained drug release, and altering the physicochemical and pharmacokinetic parameters of AmB. Although the preclinical outcome of AmB formulations is quite satisfactory, its parallel result at the clinical level is insignificant. However, the safety and efficacy of AmB therapy can be improved at the clinical stage by continuous investigation and collaboration among researchers, clinicians, and pharmaceutical companies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Birla Institute of Technology and Science Pilani (BITS Pilani), Pilani Campus, Pilani, Rajasthan 333031, India.
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER) - Ahmedabad, Gandhinagar, Gujurat 382355, India.
ORCID-Profile: Anil B Jindal
Zitieren
APA
Dash, S. K., Benival, D., & Jindal, A. B. (2024). Formulation Strategies to Overcome Amphotericin B Induced Toxicity. Molecular Pharmaceutics, 21(11), 5392-5412. https://doi.org/10.1021/acs.molpharmaceut.4c00485
Vancouver
Dash SK, Benival D, Jindal AB. Formulation Strategies to Overcome Amphotericin B Induced Toxicity. Molecular Pharmaceutics. 2024;21(11):5392-5412. doi:10.1021/acs.molpharmaceut.4c00485
BibTeX
@article{Dash2024,
author = {Dash, Sanat Kumar and Benival, Derajram and Jindal, Anil B},
title = {Formulation Strategies to Overcome Amphotericin B Induced Toxicity},
journal = {Molecular Pharmaceutics},
year = {2024},
volume = {21},
number = {11},
pages = {5392--5412},
doi = {10.1021/acs.molpharmaceut.4c00485}
}
EUVIMED